株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

転移性卵巣癌:パイプライン製品の分析

Metastatic Ovarian Cancer - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 253656
出版日 ページ情報 英文 105 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.97円で換算しております。
Back to Top
転移性卵巣癌:パイプライン製品の分析 Metastatic Ovarian Cancer - Pipeline Review, H2 2016
出版日: 2016年10月26日 ページ情報: 英文 105 Pages
概要

転移性卵巣癌は、卵巣から発生する癌ですが、体の他の部位(横隔膜、腸、頤(おとがい)、肝臓、肺など)に転移します。疲労、早期満腹感、腹部膨満、脚のむくみ、排便習慣の変化、排尿習慣の変化、腹痛、息切れなどの症状が見られます。治療は、多くの場合、外科手術、化学療法、放射線療法を併用して行われます。

当レポートでは、転移性卵巣癌に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

イントロダクション

  • 調査範囲

転移性卵巣癌の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

転移性卵巣癌:企業で開発中の治療薬

転移性卵巣癌:大学/機関で研究中の治療薬

転移性卵巣癌:パイプライン製品の概況

  • 臨床段階の製品
  • 初期段階の製品

転移性卵巣癌:企業で開発中の製品

転移性卵巣癌:大学/機関で研究中の製品

転移性卵巣癌の治療薬開発に従事している企業

  • Cellceutix Corporation
  • エーザイ
  • F. Hoffmann-La Roche Ltd.
  • Immune Design Corp.
  • Millennium Pharmaceuticals, Inc.
  • Natco Pharma Limited
  • Northwest Biotherapeutics, Inc.
  • 大日本住友製薬
  • VG Life Sciences, Inc.

転移性卵巣癌:治療薬の評価

  • 単剤製品
  • 併用製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

転移性卵巣癌:最近のパイプライン動向

転移性卵巣癌:休止中のプロジェクト

転移性卵巣癌:開発が中止された製品

転移性卵巣癌:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8564IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Metastatic Ovarian Cancer - Pipeline Review, H2 2016, provides an overview of the Metastatic Ovarian Cancer (Oncology) pipeline landscape.

Metastatic ovarian cancer is a type of cancer that originates in the ovaries, but then spreads to other areas of the body, such as the diaphragm, intestine, mentum (a fatty layer that covers and pads abdominal organs), liver or lungs. Symptoms include fatigue, getting full quickly, abdominal swelling, leg swelling, changes in bowel habits, and changes in bladder habits, abdominal pain, and shortness of breath. Metastatic ovarian cancer is often treated with a combination of therapies that can include surgery, chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Metastatic Ovarian Cancer - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Metastatic Ovarian Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Metastatic Ovarian Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Metastatic Ovarian Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 7, 9 and 2 respectively for Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 1 molecules, respectively for Metastatic Ovarian Cancer.

Metastatic Ovarian Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Metastatic Ovarian Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Metastatic Ovarian Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Metastatic Ovarian Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Metastatic Ovarian Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Metastatic Ovarian Cancer (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Metastatic Ovarian Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Metastatic Ovarian Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Metastatic Ovarian Cancer Overview
  • Therapeutics Development
    • Pipeline Products for Metastatic Ovarian Cancer - Overview
    • Pipeline Products for Metastatic Ovarian Cancer - Comparative Analysis
  • Metastatic Ovarian Cancer - Therapeutics under Development by Companies
  • Metastatic Ovarian Cancer - Therapeutics under Investigation by Universities/Institutes
  • Metastatic Ovarian Cancer - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Metastatic Ovarian Cancer - Products under Development by Companies
  • Metastatic Ovarian Cancer - Products under Investigation by Universities/Institutes
  • Metastatic Ovarian Cancer - Companies Involved in Therapeutics Development
    • Adgero Biopharmaceuticals Inc
    • Cellceutix Corporation
    • Eisai Co., Ltd.
    • F. Hoffmann-La Roche Ltd.
    • Immune Design Corp.
    • Millennium Pharmaceuticals Inc
    • MolMed S.p.A.
    • Natco Pharma Limited
    • Northwest Biotherapeutics, Inc.
    • Pfizer Inc.
    • Richter Gedeon Nyrt.
    • Sumitomo Dainippon Pharma Co., Ltd.
    • VG Life Sciences, Inc.
  • Metastatic Ovarian Cancer - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • Antisense RNAi Oligonucleotide to Replace MicroRNA-138 for Metastatic Ovarian Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • bevacizumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CMB-305 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • crizotinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DCVax-Direct - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DCVax-L - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • E-7449 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • emactuzumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • G-305 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • gedatolisib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • hydroxychloroquine + sorafenib tosylate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Kevetrin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LV-305 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NGR-hTNF - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NRCAN-019 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • orteronel - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OS-2966 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • REM-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SM-276001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Metastatic Ovarian Cancer - Dormant Projects
  • Metastatic Ovarian Cancer - Discontinued Products
  • Metastatic Ovarian Cancer - Product Development Milestones
    • Featured News & Press Releases
      • Jun 22, 2015: VG Life Sciences Granted Combination Cancer Drug Patent
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Metastatic Ovarian Cancer, H2 2016
  • Number of Products under Development for Metastatic Ovarian Cancer - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Metastatic Ovarian Cancer - Pipeline by Adgero Biopharmaceuticals Inc, H2 2016
  • Metastatic Ovarian Cancer - Pipeline by Cellceutix Corporation, H2 2016
  • Metastatic Ovarian Cancer - Pipeline by Eisai Co., Ltd., H2 2016
  • Metastatic Ovarian Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
  • Metastatic Ovarian Cancer - Pipeline by Immune Design Corp., H2 2016
  • Metastatic Ovarian Cancer - Pipeline by Millennium Pharmaceuticals Inc, H2 2016
  • Metastatic Ovarian Cancer - Pipeline by MolMed S.p.A., H2 2016
  • Metastatic Ovarian Cancer - Pipeline by Natco Pharma Limited, H2 2016
  • Metastatic Ovarian Cancer - Pipeline by Northwest Biotherapeutics, Inc., H2 2016
  • Metastatic Ovarian Cancer - Pipeline by Pfizer Inc., H2 2016
  • Metastatic Ovarian Cancer - Pipeline by Richter Gedeon Nyrt., H2 2016
  • Metastatic Ovarian Cancer - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2016
  • Metastatic Ovarian Cancer - Pipeline by VG Life Sciences, Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Metastatic Ovarian Cancer - Dormant Projects, H2 2016
  • Metastatic Ovarian Cancer - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Metastatic Ovarian Cancer, H2 2016
  • Number of Products under Development for Metastatic Ovarian Cancer - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top